Biotech News
GSK and Xenoport resubmit new drug application for Solzira™ in restless legs syndrome
GSK & XenoPort have resubmitted NDA to the FDA for approval of Solzira Extended Release Tablets, treatment of moderate-to-severe primary RLS
Biotech News
GSK & XenoPort have resubmitted NDA to the FDA for approval of Solzira Extended Release Tablets, treatment of moderate-to-severe primary RLS
GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.